uniQure N.V. entered into an underwriting agreement with Leerink Partners LLC to conduct an underwritten public offering of 4,945,055 ordinary shares at $45.50 per share, with an option for underwriters to purchase an additional 741,758 shares. The underwriters exercised the option in full on June 24, 2026, and the company expects to receive approximately $242.7 million in net proceeds. uniQure N.V. is a biotechnology company focused on gene therapy development.
